Folate and breast cancer: what about high-risk women?

被引:0
作者
Joanne Kotsopoulos
Young-In Kim
Steven A. Narod
机构
[1] Women’s College Hospital,Women’s College Research Institute
[2] University of Toronto,Dalla Lana School of Public Health
[3] University of Toronto,Departments of Medicine and Nutritional Sciences
[4] St. Michael’s Hopsital,The Keenan Research Center at the Li Ka Shing Knowledge Institute
[5] St. Michael’s Hospital,Division of Gastroenterology
来源
Cancer Causes & Control | 2012年 / 23卷
关键词
Folate; Breast cancer; High risk;
D O I
暂无
中图分类号
学科分类号
摘要
Folate is a water-soluble B-vitamin and is an important cofactor in one-carbon metabolism. This vitamin plays an important role in the pathogenesis of several chronic diseases. In recent years, there has been much interest in the relationship between folate status and breast cancer risk, particularly given the dramatic increase in dietary intake and blood serum folate levels in North America as a result of mandatory folic acid fortification and the widespread use of folic acid supplementation. The well-described dual effects of folate on carcinogenesis underscore the need to clarify the role of folate in the development and progression of breast cancer. This is of particular importance among those at high risk of developing breast cancer because of benign breast disease, a strong family history of breast cancer or an inherited mutation in BRCA1 or BRCA2. BRCA mutation carriers face a high lifetime risk of developing breast cancer, estimated at 80 % compared with 11 % in the general population. Predictive genetic testing permits the identification of these high-risk women prior to diagnosis; however, prevention is limited to surgery and chemoprevention, and the importance of modifiable risk factors such as diet and lifestyle has not been elucidated. Our goal is to develop practical and safe interventions for high-risk women leading to a decrease in the number of breast cases and deaths attributed to breast cancer.
引用
收藏
页码:1405 / 1420
页数:15
相关论文
共 741 条
  • [111] Cutler EC(2000)Experimental basis for the prevention of breast cancer Eur J Cancer 36 1275-1365
  • [112] Hawkins JW(2007)Meta-analysis of BRCA1 and BRCA2 penetrance J Clin Oncol 25 1329-707
  • [113] Harrison JH(1994)Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium Lancet 343 692-1392
  • [114] Peirce EC(2003)Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 1117-296
  • [115] Lenz CG(2002)Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer Cancer Control 9 457-S51
  • [116] Farber S(2002)Cancer incidence in BRCA1 mutation carriers J Natl Cancer Inst 94 1358-103
  • [117] Diamond LK(2010)BRCA mutations in the management of breast cancer: the state of the art Nat Rev Clin Oncol 7 702-1102
  • [118] Cole BF(2011)Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers Br J Cancer 104 1384-646
  • [119] Baron JA(2011)Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers Breast Cancer Res Treat 127 287-409
  • [120] Sandler RS(2010)Pathology of hereditary breast cancer Mod Pathol 23 S46-1098